Rosner M H, Carter D E
Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson 85721.
Fundam Appl Toxicol. 1987 Nov;9(4):730-7. doi: 10.1016/0272-0590(87)90180-1.
The increasing use of gallium arsenide (GaAs) in the electronics industry has produced the need for pharmacokinetic and toxicologic data on GaAs. The disposition in male Syrian golden hamsters (n = 4) following intratracheal instillation of GaAs (mean volume diameter 5.8 micron), arsenic (III) oxide (arsenite), and arsenic (V) oxide (arsenate) at a dose of 5 mg/kg body weight was examined. Blood, kidney, liver, and lung samples were collected at 1, 2, and 4 days after administration. Excreta were collected daily. Urinary metabolite profiles were determined after separation on a mixed anion-cation-exchange column. Total As content was analyzed by direct hydride flame atomic absorption spectrophotometry after digestion. Arsenic blood levels after GaAs, arsenite, and arsenate administration were 0.185 +/- 0.041, 0.596 +/- 0.117, and 0.310 +/- 0.045 ppm, respectively, after Day 1. Arsenic blood levels after GaAs administration increased to 0.279 +/- 0.021 ppm on Day 2 indicating continued absorption while levels decreased for the arsenite and arsenate groups. At Day 1 the liver contained 0.565 +/- 0.036, 2.62 +/- 0.26, and 0.579 +/- 0.144% of the arsenic dose of GaAs, arsenite, and arsenate, respectively. The arsenite and arsenate were rapidly excreted in the urine with almost half the dose appearing after 4 days; in contrast, only about 5% of the GaAs was found at the corresponding time. Total recoveries, as arsenic equivalents, for the three compounds were between 75 and 80%. Ratios of the two major urinary metabolites (dimethylarsinic acid/total inorganic As species) were 1.41, 1.71, and 0.983 for GaAs, arsenite, and arsenate, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
电子工业中砷化镓(GaAs)使用的增加产生了对GaAs药代动力学和毒理学数据的需求。研究了以5mg/kg体重的剂量经气管内滴注GaAs(平均体积直径5.8微米)、三氧化二砷(亚砷酸盐)和五氧化二砷(砷酸盐)后,雄性叙利亚金仓鼠(n = 4)体内的处置情况。在给药后1、2和4天收集血液、肾脏、肝脏和肺样本。每天收集排泄物。在混合阴离子 - 阳离子交换柱上分离后测定尿代谢物谱。消化后通过直接氢化物火焰原子吸收分光光度法分析总砷含量。给药后第1天,GaAs、亚砷酸盐和砷酸盐给药后的砷血水平分别为0.185±0.041、0.596±0.117和0.310±0.045ppm。GaAs给药后第2天砷血水平增加到0.279±0.021ppm,表明持续吸收,而亚砷酸盐和砷酸盐组的水平下降。第1天,肝脏分别含有GaAs、亚砷酸盐和砷酸盐砷剂量的0.565±0.036%、2.62±0.26%和0.579±0.144%。亚砷酸盐和砷酸盐迅速经尿液排出,4天后几乎有一半剂量出现;相比之下,在相应时间仅发现约5%的GaAs。三种化合物以砷当量计的总回收率在75%至80%之间。GaAs、亚砷酸盐和砷酸盐的两种主要尿代谢物的比率(二甲基砷酸/总无机砷物种)分别为1.41、1.71和0.983。(摘要截断于250字)